Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study
Latest Information Update: 13 Aug 2019
At a glance
- Drugs Memantine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Proof of concept; Therapeutic Use
- 07 Aug 2019 Primary endpoint (Changes in PANSS negative subscore between memantine and placebo treatment during trial) has been met as per results published in the Pharmacopsychiatry
- 07 Aug 2019 Results assessing effects of on cognition and negative symptoms of a 6- or 24-week memantine add-on treatment to risperidone in patients with acute or chronic schizophrenia published in the Pharmacopsychiatry
- 17 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.